

Date: November 13, 2021

To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir / Madam,

SYMBOL: AJOONI


Sub.: Approval of Un-audited Financial Results for the quarter and half year ended 30th September, 2021.


Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on 13/11/2021 at the Registered Office of the company have considered and approved the Audited Financial Statements for the quarter and half year ended 30th September, 2021. In this regards, we are enclosing herewith:

1. Un-Audited Financial Results for the quarter and half year ended on 30th September 2021.
2. Limited Review Report from the auditor for the quarter and half year ended on 30th September, 2021.

You are requested to kindly take the same on record.


Thanking You,
Yours Truly,
For Ajooni Biotech Limited

Jasjit Singh
Managing Director
DIN: 01937631



| AJOONI BIOTECH LIMITED | | | | | | |
|------------------------------------------------------------------------------------------------|-----------------|-----------------|-----------------|-------------------------------------|-------------------------------------|-----------------|
| CIN : L85190PB2010PLC040162 | | | | | | |
| STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2021 (In Lakhs) | | | | | | |
| PARTICULARS | Quarter Ended | | | | | Year Ended |
| | 30.09.2021 | 30.06.2021 | 30.09.2020 | Period Ended (UnAudited) 30.09.2021 | Period Ended (UnAudited) 30.09.2020 | 31.03.2021 |
| I Income | | | | | | |
| Revenue from operations | 1,839.19 | 1,584.62 | 1,211.04 | 3,423.81 | 2,194.20 | 5103.88 |
| Other income | 0.81 | 0.92 | 0.22 | 1.73 | 0.73 | 1.72 |
| Total income from operations | 1,840.00 | 1,585.54 | 1,211.26 | 3,425.54 | 2,194.93 | 5,105.60 |
| II Expenses | | | | | | |
| Cost of Material Consumed | 1,562.05 | 1,342.82 | 1,059.33 | 2,904.87 | 1,874.65 | 4335.59 |
| Change in Inventories | (15.22) | (1.49) | (16.66) | (16.71) | (20.69) | -34.32 |
| Employee benefit expenses | 42.03 | 38.10 | 30.43 | 80.13 | 62.48 | 114.78 |
| Finance costs | 22.18 | 13.30 | 10.36 | 35.48 | 20.80 | 58.40 |
| Depreciation and amortization expenses | 28.86 | 18.93 | 5.80 | 47.80 | 21.30 | 57.75 |
| Payment to NSF | | | | | | |
| Other expenses | 154.81 | 133.08 | 113.33 | 287.89 | 183.94 | 522.98 |
| Total expenses | 1,794.71 | 1,544.74 | 1,202.59 | 3,339.46 | 2,142.48 | 5,055.18 |
| III tax | 45.29 | 40.80 | 8.67 | 86.08 | 52.45 | 50.42 |
| IV Exceptional items | | | | | | |
| V Profit/(Loss) before tax | 45.29 | 40.80 | 8.67 | 86.08 | 52.45 | 50.42 |
| VI Tax expenses | | | | | | |
| a) Current tax | 11.78 | 10.50 | 2.25 | 22.28 | 13.6 | 15.03 |
| b) Deferred tax | 1.75 | 1.05 | - | 2.80 | - | 1.91 |
| b) Mat Credit | - | - | - | - | - | - |
| VII Net Profit/(Loss) for the period/year | 35.26 | 31.35 | 6.42 | 66.60 | 38.85 | 37.30 |
| VIII Other comprehensive income (net of tax) | | | | | | |
| profit or loss: | 4.93 | - | - | 4.93 | - | (181) |
| Total other comprehensive income | 4.93 | - | - | 4.93 | - | (181) |
| IX period/year (VII+VIII) | 40.19 | 31.35 | 6.42 | 71.53 | 38.85 | (144.03) |
| X Paid-up equity share capital (face value of the share shall be indicated) | 1,000.55 | 1,000.55 | 840.50 | 1,000.55 | 840.50 | 1,000.55 |
| XI Other equity (excluding revaluation reserve) | 637.51 | 596.69 | 755.02 | 637.51 | 787.45 | 564.51 |
| XII EPS in Rs. (Face Value of Rs.10/- each)* | | | | | | |
| -Basic | 0.35 | 0.31 | 0.08 | 0.67 | 0.46 | 0.37 |
| -Diluted | 0.35 | 0.31 | 0.08 | 0.67 | 0.46 | 0.37 |

Notes:

- The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 13.11.2021 after being reviewed by the Audit Committee.
- The company is having single segment in accordance with IND AS 108 "operating segments", and therefore segment reporting is not applicable to the Company.
- Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.

For Ajooni Biotech Limited

 Managing Director
 DIN: 01937631

Date: 13/11/2021

Place : Mohali

Statement of Assets and Liabilities
For the Year ended on 30th September 2021

| PARTICULARS | in Rs. | |
|------------------------------------|---------------------|--------------------|
| | 30TH SEPTEMBER 2021 | 31ST MARCH 2021 |
| I. ASSETS | | |
| (1) Non - Current Assets | | |
| a) Property, Plant and Equipment | 61,037,828 | 51,617,081 |
| b) Financial Assets | | |
| (1) Non-Current Investments | 10,787,122 | 11,482,856 |
| (2) Advances | | |
| c) Deffered Tax Asset | 1,745,029 | 1,465,029 |
| d) Other Non Current Assets | 703,514 | 1,407,030 |
| (2) Current Assets | | |
| a) Inventories | 30,490,225 | 53,762,090 |
| b) Financial Assets | | |
| (1) Cash & Cash Equivalent | 1,517,793 | 2,440,976 |
| (2) Short Term Loans and advances | 21,947,573 | 19,882,931 |
| (3) Trade Receivables | 159,714,538 | 137,117,389 |
| c) Other Current Asset | | 1,087,547 |
| TOTAL Rs. | 287,943,622 | 280,262,930 |
| II EQUITY AND LIABILITIES | | |
| (1) Equity | | |
| a) Equity Share Capital | 100,055,820 | 100,055,820 |
| b) Other Equity | 63,751,226 | 56,451,410 |
| (2) Non-Current Liabilities | | |
| a) Financial Liabilities | | |
| (1) Borrowings | 31,269,941 | 18,979,313 |
| (3) Current Liabilities | | |
| a) Financial Liabilities | | |
| (1) Borrowings | 43,857,734 | 48,857,260 |
| (2) Trade Payables | 46,257,706 | 54,003,957 |
| b) Other Current Liabilities | 1,573,195 | 411,890 |
| c) Current tax liabilities (Net) | 1,178,000 | 1,503,280 |
| TOTAL Rs. | 287,943,622 | 280,262,930 |

Date: 13.11.2021

Place: Mohali

For Ajooni Biotech Limited

Jasjit Singh

Managing Director (DIN: 01937631)



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

Limited Review Report on Standalone Financial Results

To Board of Directors of M/s Ajooni Biotech Limited

We have reviewed the Standalone Un-Audited Financial Result of M/s. **Ajooni Biotech Limited** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended

30th SEPTEMBER 2021 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards (' Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh & Co.
Chartered Accountants

MOHALI
CA Konia Madan
Partner

M. No 547759

Date: 13.11.2021

UDIN : 21547759AAAACW5123

House No. 1122, Sector 71, Mohali

Mobile : 096460-27023, 098120-27023 | E-mail : harjeetca@yahoo.com